Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 70 of the 76 references it cites were found in a registry or an index; 37 of the 48 sources its claims cite were checked for support.

Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024

Open access
Zhou, Guiling, Dael, Nina, Verweij, Stefan, Balafas, Spyros, Mubarik, Sumaira, Oude Rengerink, Katrien, Pasmooij, Anna Maria Gerdina, van Baarle, Debbie, Mol, Peter G.M., de Bock, Geertruida H., Hak, Eelko · 2025 · European Respiratory Review

Abstract

BACKGROUND: Up-to-date evidence from European studies on long-term vaccine effectiveness (VE) of COVID-19 vaccines is lacking. This review aimed to evaluate effectiveness and durability of primary vaccine series and boosters in preventing infection and severe outcomes in the European population. METHODS: We conducted systematic searches of PubMed and Embase up to 22 January 2024. We included observational studies that evaluated VE against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or severe disease (hospitalisation, intensive care unit admission or death) for primary series and boosters in Europe. We applied a random-effects meta-analysis model. RESULTS: We included 33 studies and over 56 million participants. The overall VE of the complete primary series against infection with any SARS-CoV-2 variant was 70.7%. VE was lower for Omicron, at 26.1%, than for pre-Omicron strains, at 77.0%. Over time, VE against infection by any variant decreased from 68.9% to 38.9% after 6 months. Boosters restored VE to 76.4% and maintained at 58.4% after 3 months. The overall VE of a complete primary series for severe outcomes due to any variant was 87.4%, with 93.3% for pre-Omicron and 62.8% for Omicron strains. Protection against severe outcomes declined less than for infection. 6 months after the primary series, the vaccine still provided over 50% protection against severe outcomes caused by Omicron. Boosters restored VE to 87.9% and maintained at 78.5% after 3 months. CONCLUSION: VE against SARS-CoV-2 infection declines markedly with time and Omicron variants. Protection against severe outcomes was more durable and resistant to viral mutation. Boosters restored protection, emphasising the need for timely booster vaccination for vulnerable populations.

Overview

CoChat Summary

TL;DR

This systematic review and meta-analysis of 33 European observational studies (>56 million participants) found that COVID-19 vaccines protect against SARS-CoV-2 infection and severe outcomes, but protection against infection wanes over time and is substantially lower for Omicron. Boosters restore protection, while protection against severe outcomes is more durable and less affected by viral mutation.

Key findings

  • Primary-series VE against infection with any variant was 70.7% (95% CI 62.4–77.1), falling from 68.9% (95% CI 59.9–75.9) at 0–3 months to 38.9% (95% CI 28.8–47.5) after >6 months. VE was 77.0% (95% CI 70.4–82.1) for pre-Omicron versus 26.1% (95% CI 21.1–30.8) for Omicron.
  • Primary-series VE against severe outcomes with any variant was 87.4% (95% CI 81.4–91.4): 93.3% (95% CI 90.0–95.4) for pre-Omicron and 62.8% (95% CI 50.4–72.1) for Omicron. More than 6 months after primary series, Omicron severe-outcome VE remained above 50% at 52.9% (95% CI 42.6–61.3).
  • Boosters restored VE against infection to 76.4% (95% CI 67.0–83.1) overall and maintained it at 58.4% (95% CI 38.9–71.6) after >3 months. For severe outcomes, booster VE was 87.9% (95% CI 83.8–91.0) overall and 78.5% (95% CI 69.3–85.0) after >3 months.
  • Among 33 included studies, 15 were low risk, 8 moderate risk and 10 high risk of bias; no study was critical risk or excluded from meta-analysis on quality grounds.

Methods

  • Systematic review and random-effects meta-analysis following PRISMA, registered as PROSPERO CRD42024529854; PubMed and Embase were searched from 1 January 2020 to 22 January 2024, restricted to English-language observational studies conducted in Europe in adults aged ≥16 years.
  • Included 33 studies (17 case–control, 12 cohort, 4 both) with >56 million participants; eligible VE estimates compared complete primary series or boosters with unvaccinated participants for RT-PCR-confirmed infection, hospitalisation, ICU admission or all-cause death.
  • Analyses pooled adjusted VE estimates after log-odds conversion using inverse-variance weighting and restricted maximum-likelihood between-study variance; stratified by variant, time since last dose, vaccine type, study design, prior infection adjustment and risk of bias.

Limitations

  • The paper states that hospitalisation, ICU admission and death were combined into a composite severe-outcome category because of limited power for individual outcomes, and that studies varied in whether they measured hospitalisation with versus due to COVID-19. It also notes limited generalisability outside Europe, inclusion of only four European-licensed vaccines, RT-PCR-only diagnosis, high I² heterogeneity, English-language restriction, lack of Omicron subvariant analyses, difficulty evaluating long-term second/third boosters, and no consideration of concomitant preventive measures, vaccine hesitancy or racial disparities.
  • The text makes evident that all included studies were observational, so residual confounding is possible despite extraction of adjusted estimates; many studies had moderate or high risk of bias, commonly from missing data and selection bias related to prior infection.
  • The very high I² values reported for most pooled estimates indicate substantial unexplained between-study variation, which the authors state limits generalisability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1183/16000617.0222-2024

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE 1 Vaccine effectiveness (VE) of primary series or booster against severe acute respiratory syndrome coronavirus 2 infection. The main data points represent the result of the meta-analysis along with the error bars representing the 95% confidence interval. The lighter data points represent the individual VE estimates pooled in the meta-analysis.
FIGURE 1 Vaccine effectiveness (VE) of primary series or booster against severe acute respiratory syndrome coronavirus 2 infection. The main data points represent the result of the meta-analysis along with the error bars representing the 95% confidence interval. The lighter data points represent the individual VE estimates pooled in the meta-analysis.CC BY-NC · PubMed Central
FIGURE 2 Vaccine effectiveness (VE) of primary series or booster against severe COVID-19 outcomes. Severe outcomes included hospitalisation, intensive care unit admission and death. The main data points represent the result of the meta-analysis along with the error bars representing the 95% confidence interval. The lighter data points represent the individual VE estimates pooled in the meta-analysis.
FIGURE 2 Vaccine effectiveness (VE) of primary series or booster against severe COVID-19 outcomes. Severe outcomes included hospitalisation, intensive care unit admission and death. The main data points represent the result of the meta-analysis along with the error bars representing the 95% confidence interval. The lighter data points represent the individual VE estimates pooled in the meta-analysis.CC BY-NC · PubMed Central

Verification

Claims the paper makes

24 Valid · 6 Not valid · 3 Not checked · 99 Own results and interpretations

75 more claims · 8 with their cited sources checked

Create a free account to see all 132 claims and to verify the 4 references still open.

See all claims — free account
  • It may state two separate claims as one. 37
  • Probably not a substantial claim. 17
  • The quote only partly states this claim. 3

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 76 references

Research works printed but not linked: 1

  1. 10.1056/NEJMOA2113017/SUPPL_FILE/NEJMOA2113017_DATA-SHARING.PDF · doi:10.1056/nejmoa2113017/suppl_file/nejmoa2113017_data-sharing.pdf

Cited by

See all 35

Metadata

Authors
Zhou, G., Dael, N., Verweij, S., Balafas, S., Mubarik, S., Oude Rengerink, K., Pasmooij, A. M. G., van Baarle, D., Mol, P. G. M., de Bock, G. H., & Hak, E.
Affiliations
  • University of Groningen (NL)
  • Utrecht University (NL)
  • University Medical Center Groningen (NL)
Corresponding author
Zhou, Guiling
Venue
European Respiratory Review
Published
2025-01
Volume
34
Issue
175
Pages
240222
ISSN
  • 0905-9180 (ISSN-L)
  • 1600-0617
OpenAlex
W4407751397
Cited by
34
References
76
Citations by year
2026: 19 · 2025: 15
FWCI
5.92
Type
journal article
Language
en
Open access
Locations
  • European Respiratory Review (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
COVID-19 vaccines, SARS-CoV-2, vaccine effectiveness, Omicron variant, booster vaccination, waning immunity, severe outcomes, hospitalization, intensive care unit admission, vaccine durability, European adults
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Vaccines, Vaccine Efficacy, Adult, Europe, Humans, Severity of Illness Index, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024. https://app.cochat.ai/papers/10.1183/16000617.0222-2024
The paper
Zhou, G., Dael, N., Verweij, S., Balafas, S., Mubarik, S., Oude Rengerink, K., Pasmooij, A. M. G., van Baarle, D., Mol, P. G. M., de Bock, G. H., & Hak, E. (2025). Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024. European Respiratory Review. https://doi.org/10.1183/16000617.0222-2024

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.